Global Healthcare Stocks Decline Following Trump’s Selection of RFK Jr for Health Secretary

On Friday, stock values for global vaccine manufacturers and healthcare companies experienced a significant decline. This downturn occurred as investors expressed concerns that Donald Trump’s selection of Robert F Kennedy Jr for the role of US Health Secretary might introduce new difficulties for the industry. Kennedy, recognized for his skepticism regarding vaccines, has pledged, if confirmed, to leverage the position to “crack down on “Big Pharma”.” This announcement led to widespread selling within the sector. Specifically in the US, Pfizer’s shares fell by over 4%, and Moderna’s by approximately 7%. Concurrently, AstraZeneca and GSK, both listed in the UK, saw their shares decrease by more than 3%. Russ Mould, who serves as investment director at AJ Bell, commented that the appointment had “spooked” shareholders, even with lingering questions about the potential methods the new administration might employ to enact its stated intentions. He added, “The impact on the sector is hard to judge fully at this stage but, at the very least, it will cause a good deal of uncertainty.” The US health secretary is responsible for a vast agency that supervises a broad range of areas, from food safety to medical research and welfare initiatives. Numerous public health officials, who have criticized Kennedy (often referred to by his initials RFK Jr), have condemned his history of disseminating health information that scientists deem false. However, the former environmental lawyer has attracted supporters by leveraging skepticism among those who perceive US regulators as overly compliant with large food and medical corporations. Prior to endorsing Trump, Kennedy had unsuccessfully sought the presidency as a third-party candidate. His campaign platform advocated for stricter controls on food chemicals and dyes, the elimination of ultra-processed foods from school lunch programs, and mandating greater transparency from pharmaceutical companies regarding vaccines. Should his nomination receive Senate approval and he gain the authority to implement his commitments, it would signify a shift in policy. This change would diverge not only from the Biden administration’s stance but also from Trump’s initial term, during which the government heavily invested in assisting companies with Covid vaccine development while adopting a less interventionist regulatory approach. Nevertheless, Trump’s prior efforts to reduce drug prices, such as facilitating medicine imports from Canada, had also caused apprehension within the industry. Paul Chaplin, chief executive of the Danish company Bavarian Nordic, whose shares declined by over 15%, stated that the industry would need to observe what actual changes occur. He did, however, point out that policies implemented during Trump’s first term had, in fact, benefited his company’s mpox and smallpox vaccine operations. Chaplin expressed his belief that a second Trump term, with RFK Jr serving as health secretary, might prove advantageous for certain segments of his business while increasing risks for others, recognizing that the prevailing uncertainty had impacted share values. He remarked, “It is too early to say and we have to wait and see how things develop,” during an interview on the BBC’s World Business Report radio programme. Across Europe, Novo Nordisk, the Danish-listed manufacturer of Ozempic, concluded trading with its shares down by over 5%. Similarly, Sanofi of France, a prominent producer of flu vaccines, experienced a share decline of more than 3% in Paris. Copyright 2024 BBC. All rights reserved. The BBC bears no responsibility for the content found on external websites. Information regarding our approach to external linking is available.